Clinical Trial

Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 20, 2022 (before its estimated June 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm, prospective, open-label observational clinical study to evaluate the efficacy and safety of Bevacizumab combined with Oxaliplatin and TAS-102 in patients with advanced unresectable rectal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-05-03.
Trial Details
NCT Number NCT05364489
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions Advanced Colorectal Cancer
Enrollment 20 participants
Start Date 2022-06-15
Primary Completion 2025-06-15 (estimated)
Study Completion 2027-06-15 (estimated)
Updated on ClinicalTrials.gov 2022-05-20